A healthy, nonepileptic 16-month-old child ingested a massive overdose (approximately 4000 rag) of valproic acid (VPA). Upon admission to the hospital, he was in a deep coma and had generalized hypotonicity and no response to pain. His serum and urinary concentrations of VPA were 1316.2 and 3289.5 pg/mL, respectively. Urinary concentrations of the ~-oxidation metabolites of VPA were low, whereas concentrations of (0-and (01-oxidation metabolites were high. Moreover, 4-en-valproate (a potential hepatotoxin) was detected in the urine. Gastric lavage and general supportive measures were undertaken, including intravenous infusion to increase urine output and oral t-carnitine to correct hypocarnitinemia. Subsequently, the ~-oxidation metabolites increased, the co-and (01-oxidation metabolites decreased, and 4-en-valproate was no longer detected. The patient recovered completely and was discharged on the eighth hospital day without any sequelae. This case suggests that enhanced drug excretion and t-carnitine supplementation may prevent potentially fatal hepatic dysfunction after VPA overdose.
Introduction
Valproic acid (VPA) is a chemically unique antiepileptic agent with a broad spectrum of action. Although VPA accounted for approximately 55% of all prescriptions for antiepileptic therapy in Japan from January to May in 1994 (internal data; Kyowa Hakko Co., Tokyo, Japan), acute toxicity in healthy individuals has rarely been reported (1,2).
Adverse reactions to VPA include digestive symptoms such as nausea and vomiting (3) , metabolic disorders such as hyperammonemia (4) , and teratogenetic effects such as neural tube defects and spina bifida (5) . In addition, liver dysfunction requires caution because it sometimes influences the prognosis. The liver dysfunction caused by VPA appears to be similar in mechanism to that seen in Reye's syndrome and Reye-like syndrome, in which hepatic mitochondrial dysfunction reduces *Address correspondence to Hiroyasu Ishikura, Department of Emergency and Critical Care Medicine, Kansai Medical University, Fumizono-cho 10-15, Moriguchi, Osaka, 570 Japan.
Case History
A previously healthy ]6-month-old child accidentally ingested 4000 mg (412.4 mg/kg) of VPA tablets (Depakene R| Kyowa Hakko), a medication that his mother had been prescribed after suffering a traumatic intracerebral hemorrhage. Approximately 2 h later, his mother noticed that the child's breathing was abnormal and took him to a local hospital where gastric lavage was performed for suspected VPA intoxication. Then the child was referred to our emergency care unit.
Upon transfer, the child was in a deep coma and showed no response to pain. His pupils were equal, but their reaction to light was slow. Neurological examination showed decreased deep tendon reflexes but no pathological reflexes. His heart rate was 131 beats/rain, his blood pressure was 140/70 mmHg, and his temperature was 36.7~ His respiration was somewhat shallow but not abnormal.
Laboratory studies upon admission showed slight hyperglycemia (186 mg/dL), hypoproteinemia (5.6 g/dL), and an increased creatinine kinase concentration (263 IU/L). Liver and renal function tests were normal (33 IU/L for aspartate aminotransferase, 11 IU/L for alanine aminotransferase, 428 IU/L for lactate dehydrogenase, 0.5 mg/dL for bilirubin, 14 mg/dL for blood urea nitrogen, and 0.6 mg/dL for creatinine). There was a slight increase of the white blood cell count (9400/mm3), and metabolic acidosis was observed (FiO2, 0.21; pH 7.347; PCO2, 31.8 mmHg; PO2, 79.1 mmHg; HCO3-, 17 .2 mEq/L; base excess, -7.3 mEq/L; O~, 94.9% saturated). The VPA concentrations in blood and urine were extremely high at 1316.2 and 3289.5 I~g/mL, respectively, approximately 3 h after drug ingestion.
Gastric ]avage was initiated immediately after transfer, and a white precipitate was observed in the fluid that was obtained. After gastric lavage, 10 g of activated charcoal was injected through the nasogastric tube to reduce drug absorption. Furthermore, intravenous fluid was rapidly infused (4.0 mL/kg per hour) to help clear VPA from the blood by promoting diuresis, and sodium bicarbonate (60 mL per day) was administered intravenously to increase the glomerular filtration rate by alkalinizing the urine. In addition, to prevent the development of hepatic mitochondrial dysfunction, 100 mg/kg of L-carnitine (LCartin| Ohtsuka Pharmaceutical, Tokyo, Japan) was administered upon admission, followed by 250 mg every 8 h for 4 days.
The patient's level of consciousness improved as the VPA concentrations in the blood and urine decreased, and his consciousness became clear on the fourth hospital day when the blood VPA concentration reached the therapeutic range (50-100 ]Jg/mL). During this time, his vital signs remained fairly stable, and the major laboratory parameters stayed within the normal range.
No abnormalities were observed on the computed tomography scan of his head and the electroencephalogram performed on the second hospital day, and the patient was discharged without sequelae on the eighth day.
Methods
The serum concentration of VPA and the urinary concentrations of the drug and nine metabolites were assayed by the previously described gas-liquid chromatographic-mass spectrometric method of Tatsuhara et al. (12) . These metabolites included the following: [3-oxidation metabolites, 2-propyl-2-pentenoic acid (2-en-VPA), 3-hydroxy-2-propylpentanoic acid (3-OH-VPA), and 3-oxo-2-propylpentanoic acid (3-keto-VPA); co-oxidation metabolites, 5-hydroxy-2-propylpentanoic acid (5-OH-VPA), 2-propylglutaric acid (PGA), and 2-propyl-4-pentenoic acid (4-en-VPA); and col-oxidation metabolites, 4-hydroxy-2-propylpentanoic acid (4-OH-VPA), 4-oxo-2-propylpentanoic acid (4-keto-VPA), and 2-propyl-3-pentenoic acid (3-en-VPA).
Results
The daily changes of the VPA concentrations in serum and urine are shown in Figure 1 . The urine volume and urinary clearance of VPA are shown in Table I . The serum and urinary VPA concentrations were extremely high upon hospitalization, being 1316.2 and 3289.5 ~g/mL, respectively. The serum VPA concentration subsequently decreased, and it fell to the therapeutic range (50-100 IJg/mL) by hospital day 4. In contrast, the urinary VPA concentration peaked at 8909.5 pg/mL on day 2 and then decreased steadily. VPA concentrations were very low in both the urine and blood on day 6. The urine volume was 3.5-4.0 mL/kg per hour on days 2--4. Urinary VPA clearance peaked at 8.29 mL/min on day 2 and was approximately 5.5-fold higher than at the time of hospitalization. These findings reflected the effects of rapid intravenous fluid infusion (4.0 mL/kg per hour) and urinary alkalinization.
The urinary concentrations of organic acids and VPA metabolites are shown in Table II . High concentrations of cooxidation metabolites (5-OH-VPA and PGA) and col-oxidation metabolites (4-OH-VPA and 4-keto-VPA) were observed.
On the other hand, the concentrations of [3-oxidation metabolites (2-en-VPA, 3-OH-VPA, and 3-keto-VPA), usually the major metabolic pathway in patients on VPA monotherapy (12), were relatively low. The most striking abnormality in our patient was the appearance of 4-en-VPA in the urine. After administration of L-carnitine began, ~-oxidation metabolites increased and the co-and col-oxidation metabolites decreased from hospital day 2. In addition, 4-en-VPA became almost undetectable, indicating a return to normal VPA metabolism.
Discussion
VPA is a simple, eight-carbon, branched-chain fatty acid, which is normally mainly metabolized in the liver by glucuronic acid conjugation and [~-oxidation (13). Tatsuhara et al. (12) determined nine metaboIites of VPA in the urine of 12 epileptic patients on regular VPA monotherapy who did not show any evidence of intoxication. They found that ~-oxidation metabolites were the major metabolites of VPA in the urine (69.61 + 7.28%), whereas co-and col-oxidation metabolites were relatively less important (14.36 • 6.15% and 16.03 • 6.48%, respectively). In contrast with these data, our patient showed a decrease of [3-oxidation metabolites and an increase of co-and col-oxidation metabolites upon hospitalization before L-carnitine treatment. In addition, the urinary 4-en-VPA concentration was increased (Table II) .
It has been reported that long-term or high-dose VPA therapy induces hypocarnitinemia, which appears to inhibit [3-oxidation, whereas the co-and col-oxidation pathways are increased in compensation (14, 15) . When the carnitine concentration decreases, the mitochondrial free CoA concentration is thought to decline and thus impair the [3-oxidation of VPA (15) . In addition, the production of 4-en-VPA by abnormal metabolism appears to have a toxic effect on the liver (16, 17) .
Accordingly, L-carnitine was administered to our patient in order to correct hypocarnitinemia and return VPA metabolism to the normal [3-oxidation pathway. After hospital day 2, !B-oxidation increased, and co-and col-oxidation decreased as a result of L-carnitine therapy. In addition, the urinary 4-en-VPA concentration decreased rapidly, and the patient recovered well without developing serious liver dysfunction. Murakami et al. (15) analyzed the urinary metabolites of VPA and carnitine metabolism in an 11-year-old epileptic child on VPA therapy. The concentration-time profile of VPA metabolites in his urine before and after L-carnitine administration was similar to that in our case. The [B-oxidation metabolites of VPA were undetectable in the urine before L-carnitine administration but were detected in significant amounts after the start of ~.-carnitine treatment. On the other hand, the o)-and col-oxidation metabolites showed inverse changes relative to the [3-oxidation metabolites.
In our patient, the urinary concentrations of free and total carnitine were markedly decreased on the day of admission. After administration of L-carnitine, the creatinine urinary acyl and total carnitine concentra-
tions showed a marked increase. On hospital day 1, the acetylcarnitine/acylcarnitine 0.6 ratio was 90%, and this ratio was decreased o. 3 after L-carnitine treatment.
Our patient received nothing orally and Abbreviations: 2-en-VPA, 2-propyl-2-pentenoic acid; 3-OH-VPA, 3-hydroxy-2-propylpentanoic acid; 3-keto-VPA, 3-oxo-2-propylpentanoic acid; 5-OH-VPA, 5-hydroxy-2-propylpentanoic acid; PGA, 2-propylglutaric acid; 4-en-VPA, 2-propyl-4-pentenoic acid; 4-OH-VPA, 4-hydroxy-2-propylpentanoic acid; 4-keto-VPA, 4-oxo-2-propylpentanoic acid; 3-en-VPA, 2-propyl-3-pentenoic acid. * Numbers in parentheses show the percentage of each metabolite versus the total VPA concentration in urine, bCarnitine administration began after the 0:00 a.m. reading on day 2. ND = Not detectable.
been studied in epileptic patients on VPA therapy (14-17), and Dupuis et al. (18) were the only authors to successively follow the changes of VPA metabolites in a healthy individual with intoxication. As was shown in our case, they found decreased 8-oxidation and elevated ~ and col-oxidation in the early phase of acute VPA intoxication. When monitoring was continued in our patient after c-carnitine administration, the normalization of VPA metabolism was noted. This result was consistent with the changes seen in patients on regular VPA therapy in whom liver dysfunction is relieved by carnitine administration. Although the blood carnitine concentration was not meaSured, these results suggested that hypocarnitinemia occurs in association with acute hepatic dysfunction after VPA intoxication. Thus, our case suggested that L-carnitine administration is as effective in preventing hepatic dysfunction after acute VPA intoxication in healthy individuals as it is for preventing the development of hepatic dysfunction resembling that in Reye's or Reye-like syndrome dtiring regular VPA therapy (19) . The general treatment of VPA intoxication is to promote elimination of the drug with forced diuresis by fluid loading and increasing the glomerular filtration rate by urinary alkalization, both producing good results. Hemodialysis, as well as hernabsorption therapy, has also been reported to be useful (20) . However, because VIA is 90% protein bound (21), elimination by dialysis is unlikely to be very effective. In addition, hernabsorption therapy has been suggested to achieve inadequate drug clearance in some reports (2,22), so there is still no consensus about the value of these two methods. The blood half-life of VPA is fairly short (8-20 h) (21,23) , and it appears from our experience that a VPA concentration of greater than 1000 pg/mL can be reduced to the therapeutic range (50-100 Bg/mL) by forced diuresis with fluid loading over 2-3 days. Therefore, active blood clearance procedures do not appear to be necessary after VPA overdose as long as no complications occur other than disturbance of consciousness.
In conclusion, the prognosis appears likely to be good if elimination of the drug is promoted in the early period after VPA overdose and hepatic dysfunction is prevented by L-carnitine administration.
